At a Glance

ASKA Pharmaceutical Holdings' business operations include a pharmaceuticals business, an animal health business, and a testing business. Rather than focusing solely on promoting each business individually, we are using alignment between businesses to drive synergy that will maximize revenue. Here we highlight our initiatives in female healthcare, a key focus area in the pharmaceutical business, which accounts for approximately 90% of the Group's net sales.

Net sales in FY2022 ¥60,461 million

Pharmaceutical Business: Main Target Diseases

Internal Medicine (Gastroenterology and Thyroid)

- · Hepatic encephalopathy
- Hyperthyroidism
- Hypothyroidism

Urology

- Benign prostatic hyperplasia

- · Prostate cancer

Livestock and Fisheries

- Pharmaceuticals for breeding
- Antibacterial pharmaceuticals
- Gastrointestinal
- Antiparasitic
- pharmaceuticals Pharmaceuticals
- pharmaceuticals Feed additives
- affecting metabolism
- Mixed feed
- Antibiotics
- Feed materials

Companion Animals

- Cardiovascular pharmaceuticals
- · Pharmaceuticals affecting metabolism
- Topical pharmaceuticals
- Dietary supplements
- Antiparasitic pharmaceuticals
- · Hair stress hormone level testing and diagnostics
- Skincare

Animal Health Business: Main Products

Testing Business: Main Services and Products

· Hair hormone level measurement kit-testosterone

Nail stress hormone level testing and diagnostics

Obstetrics and Gynecology (Ob/Gyn)

Infertility

Imminent miscarriage/

· Iron deficiency anemia

premature birth

· Labor induction

Menopause

STD/Infection

· Uterine fibroids

Endometriosis

Dysmenorrhea

Contraception

contraception

Emergency

· Menstrual disorders

Microdetermination of **Endogenous Hormones**

• High sensitivity measurement using LC-MS/MS

and refinement techniques, derivatization)

· Multi-item simultaneous steroid hormone

• Ultra-high-sensitive estrogen measurement

Measurements Using Non-Invasive

· Hair hormone level measurement kit-DHT

Samples (Hair, nails, etc.)

(androgenetic alopecia)

(male menopausal disorder)

(Optimization of measurement conditions, separation

ASKA Pharmaceutical—a Focus on Women's Healthcare

Ob/Gvn

Leading company

No. 1 domestic market share*

In the second half of FY2022, we achieved the highest sales in the Ob/Gyn field in Japan. We are promoting a variety of initiatives in addition to pharmaceuticals, including disseminating information on women's health.

* Company estimates

▶See page **24** for details.

Female Healthcare Research

Since our founding in 1920, we have used hormonal research to address female healthcare. We will continue creating a wide variety of drugs in line with the needs of the times so that we can continue contributing to women's health.

See pages **6-7** for details.

Share of Thyroid Products Market

The continuous development of our business draws on our 100 years of experience and expertise in the thyroid area. We will strive to ensure quality and stable supply, continuing to contribute to society as a leading company in the thyroid area.

See page **27** for details.

R&D Expenses

We are a pharmaceutical manufacturer that develops new drugs with a focus on the three priority areas of internal medicine, Ob/Gyn, and urology. We will work with companies in Japan and abroad, accelerating open innovation to provide innovative new drugs.

See pages **40-41** for details.

Uterine Fibroids and Endometriosis Agents (FY2023 Net Sales Forecast)

RELUMINA, a uterine fibroids and endometriosis agent, is a growth driver. In the fifth year since its launch in 2019, it is expected to reach annual sales of ¥10.0 billion. We expect it to meet its mediumterm management plan target ahead of schedule.

See page **27** for details.

Diversity & Inclusion

20.8%

Percentage of Female Manager Candidates

We believe that achieving sustainable growth and enhancing corporate value depend on respecting diverse values. We aim to create a workplace environment in which all employees, regardless of age or attributes, can play an active role.

▶See page **36** for details.

8 ASKA HD REPORT 2023 ASKA HD REPORT 2023 9